Literature DB >> 22170045

Matrine modulates HSC70 levels and rescues ΔF508-CFTR.

Anna Basile1, Maria Pascale, Silvia Franceschelli, Erika Nieddu, Marco T Mazzei, Paola Fossa, Maria Caterina Turco, Mauro Mazzei.   

Abstract

Cystic fibrosis transmembrane conductance regulator (CFTR) is a cAMP-dependent Cl(-) channel located in the plasma membrane, and its malfunction results in cystic fibrosis (CF), the most common lethal genetic disease in Caucasians. Most CF patients carry the deletion of Phe508 (ΔF508 mutation); this mutation prevents the delivery of the CFTR to its correct cellular location, the apical (lumen-facing) membrane of epithelial cells. Molecular chaperones play a central role in determining the fate of ΔF508-CFTR. In this report, we show that the Matrine, a quinolizidine alkaloid, downregulates the expression of the molecular chaperone HSC70 and increases the protein levels of ΔF508-CFTR in human alveolar basal epithelial cells (A549 cell line), stably transfected with a ΔF508-CFTR-expressing construct. Moreover, Matrine induced ΔF508-CFTR release from endoplasmic reticulum to cell cytosol and its localization on the cell membrane. Interestingly, downregulation of HSC70 resulted in increased levels of ΔF508-CFTR complexes with the co-chaperone BAG3 that in addition appeared to co-localize with the mutated protein on the cell surface. These results shed new light on ΔF508-CFTR interactions with proteins of the chaperones/co-chaperones system and could be useful in strategies for future medical treatments for CF.
Copyright © 2011 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22170045     DOI: 10.1002/jcp.24028

Source DB:  PubMed          Journal:  J Cell Physiol        ISSN: 0021-9541            Impact factor:   6.384


  5 in total

1.  Molecular Chaperones as Targets to Circumvent the CFTR Defect in Cystic Fibrosis.

Authors:  Rebecca A Chanoux; Ronald C Rubenstein
Journal:  Front Pharmacol       Date:  2012-07-17       Impact factor: 5.810

2.  Matrine in association with FD‑2 stimulates F508del‑cystic fibrosis transmembrane conductance regulator activity in the presence of corrector VX809.

Authors:  Barbara Marengo; Andrea Speciale; Lisa Senatore; Silvano Garibaldi; Francesca Musumeci; Erika Nieddu; Benedetta Pollarolo; Maria Adelaide Pronzato; Silvia Schenone; Mauro Mazzei; Cinzia Domenicotti
Journal:  Mol Med Rep       Date:  2017-10-06       Impact factor: 2.952

3.  BAG3 promotes stem cell-like phenotype in breast cancer by upregulation of CXCR4 via interaction with its transcript.

Authors:  Bao-Qin Liu; Song Zhang; Si Li; Ming-Xin An; Chao Li; Jing Yan; Jia-Mei Wang; Hua-Qin Wang
Journal:  Cell Death Dis       Date:  2017-07-13       Impact factor: 8.469

4.  p53-dependent transcriptional suppression of BAG3 protects cells against metabolic stress via facilitation of p53 accumulation.

Authors:  Jia-Mei Wang; Bao-Qin Liu; Zhen-Xian Du; Chao Li; Jia Sun; Jing Yan; Jing-Yi Jiang; Hua-Qin Wang
Journal:  J Cell Mol Med       Date:  2019-10-28       Impact factor: 5.310

5.  Lumacaftor and Matrine: Possible Therapeutic Combination to Counteract the Inflammatory Process in Cystic Fibrosis.

Authors:  Michela Pecoraro; Silvia Franceschelli; Maria Pascale
Journal:  Biomolecules       Date:  2021-03-13
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.